Hodgkin's%20lymphoma News

News

Geriatrician Dr Carol Tan speaks about the dangers of polypharmacy in elderly patients

Does polypharmacy affect survival in older patients with haematological malignancy?

Stephen Padilla, 20230710120000

Polypharmacy does not appear to result in poorer treatment response and survival in older patients with different haematological malignancies, as shown in a study presented at the recent EHA 2023.

Original New Drug Application Approvals by US FDA (16-30 June 2023)

20230701000000

New drug applications approved by US FDA as of 16-30 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

ZUMA-5: CAR T-cell therapy shows promise in R/R non-Hodgkin lymphoma

Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma

Stephen Padilla, 20230622120000

Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.

Original New Drug Application Approvals by US FDA (01-15 June 2023)

20230616065822

New drug applications approved by US FDA as of 01-15 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

$Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma$

Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma

20230325140000

Adding pembrolizumab to chemotherapy consisting of ifosfamide, carboplatin, and etoposide (ICE) in the treatment of patients with relapsed or refractory classic Hodgkin lymphoma appears to be well tolerated and associated with better outcomes in comparison with reports from studies on chemotherapy-only regimens, according to data from a phase II study.

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

Jairia Dela Cruz, 20230308100000

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

Anthracycline treatment for cancer linked to increased risk of congestive heart failure

20230207150000

The use of anthracyclines in the treatment of cancer appears to carry a twofold risk of congestive heart failure, according to a study.

Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors

20230206150000

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.

Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL

Audrey Abella, 20221025100000

In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).

Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males

Christina Lau, 20220608043517

The incidence of Hodgkin lymphoma has increased in the past decade, especially in Asian countries, females, and the younger population, a global study has shown.

Product Highlight - Lanzotred

13 Sep 2023

Enzalutamide 40 mg softcap

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

ALL treatment: Current settings, future goals

Roshini Claire Anthony, 08 Jan 2021

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.